ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 12, 2018, and June 15, 2018. ENDRA Life Sciences Inc. is an emerging growth company focused on developing Thermo Acoustic Enhanced Ultrasound (TAEUS) technology for clinical use. The report details the results of the 2018 Annual Meeting of Stockholders and a strategic shift regarding its pre-clinical business operations.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue totals, profit margins, debt levels, or liquidity metrics for the reporting period. The only specific financial data disclosed relates to the pre-clinical business segment:
- Pre-clinical Revenue (Q1 2018): $6,174 generated from service activity on the existing installed base of Nexus 128 systems.
Material Changes and Strategic Shifts
On June 15, 2018, the Company announced a strategic pivot to focus resources on its clinical TAEUS technology. Consequently, it will explore strategic alternatives for its pre-clinical business, including a potential sale. The Company has committed to honoring existing contracts for the Nexus 128 system, which has been marketed since 2010 for pre-clinical imaging.
Corporate Governance and Voting Results
At the Annual Meeting held on June 12, 2018, stockholders approved the following:
- Director Elections: All five nominees (Francois Michelon, Anthony DiGiandomenico, Dr. Sanjiv Sam Gambhir, Michael Harsh, and Alexander Tokman) were elected. Broker non-votes were significant, totaling 974,777 shares for each nominee.
- Omnibus Plan Amendment: Stockholders approved the First Amendment to the 2016 Omnibus Incentive Plan. Votes were 1,118,754 For, 130,918 Against, and 1,100 Abstain.
- Auditor Ratification: The appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was ratified. Votes were 2,141,783 For, 79,835 Against, and 3,931 Abstain.
Risks and Forward-Looking Statements
The Company highlights inherent risks regarding the development of commercially feasible technology, receipt of regulatory approvals, market acceptance, and the ability to secure development partners. The exploration of strategic alternatives for the pre-clinical business involves uncertainties regarding the ability to consummate any potential sale.
Investor Verification Checklist
- Verify the terms of the First Amendment to the 2016 Omnibus Incentive Plan in the 2018 Proxy Statement.
- Monitor updates regarding the potential sale or strategic alternatives for the pre-clinical Nexus 128 business.
- Review the Company's progress in developing the clinical TAEUS technology and securing regulatory approvals.
- Assess the impact of the strategic shift on future revenue streams, given the minimal Q1 2018 revenue from the pre-clinical segment.